The following is a summary of “Prediction and prognostic potential of NR3C1 gene expression level in DLBCL patients,” published in the August 2023 issue of Hematology by Yan et al.
Effective treatment and prognosis for Diffuse Large B-cell lymphoma (DLBCL), a common subtype of Non-Hodgkin Lymphoma (NHL), require further exploration.
Researchers performed a retrospective study to determine the prognostic potential of NR3C1 gene expression level in DLBCL patients.
They categorized 952 DLBCL patients into high-expression and low-expression NR3C1 groups, comparing the baseline characteristics. Next, multivariate analysis was employed to predict age, pathology, ECOG score, lactate dehydrogenase (LDH) ratio, and NR3C1 expression level as dependent variables. Finally, the progression-free survival (PFS) and overall survival rate (OS) in DLBCL patients based on NR3C1 expression were assessed.
The results showed that DLBCL patients with high NR3C1 expression had a significantly better prognosis than those with low NR3C1 expression, with an OS difference (P<0.0001). In DLBCL patients receiving CHOP therapy, high NR3C1 expression was also linked to improved OS (P=0.028).
Investigators concluded that in multivariate analysis, NR3C1 high expression was an independent prognostic factor that predicted a longer DLBCL (OS, P=0.0003).
Source: tandfonline.com/doi/full/10.1080/16078454.2023.2251199
